148 related articles for article (PubMed ID: 38173594)
1. Preparation of novel S-allyl cysteine chitosan based nanoparticles for use in ischemic brain treatment.
Khan MF; Ahmad N; Alkholifi FK; Ullah Z; Khalid MS; Akhtar S; Farooqui S; Khan N; Chaudhary AA; Alawam AS; Ali MAM
RSC Adv; 2024 Jan; 14(1):160-180. PubMed ID: 38173594
[No Abstract] [Full Text] [Related]
2. A Chitosan-PLGA based catechin hydrate nanoparticles used in targeting of lungs and cancer treatment.
Ahmad N; Ahmad R; Alrasheed RA; Almatar HMA; Al-Ramadan AS; Buheazah TM; AlHomoud HS; Al-Nasif HA; Alam MA
Saudi J Biol Sci; 2020 Sep; 27(9):2344-2357. PubMed ID: 32884416
[TBL] [Abstract][Full Text] [Related]
3. Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy.
Ahmad N; Ahmad R; Alrasheed RA; Almatar HMA; Al-Ramadan AS; Amir M; Sarafroz M
Pharmaceutics; 2020 Feb; 12(3):. PubMed ID: 32120778
[TBL] [Abstract][Full Text] [Related]
4. Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment.
Ahmad N; Al-Subaiec AM; Ahmad R; Sharma S; Alam MA; Ashafaq M; Abdur Rub R; Ahmad FJ
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):475-490. PubMed ID: 30739499
[TBL] [Abstract][Full Text] [Related]
5. Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia.
Ahmad N; Ahmad R; Ahmad FJ; Ahmad W; Alam MA; Amir M; Ali A
Saudi J Biol Sci; 2020 Jan; 27(1):500-517. PubMed ID: 31889876
[TBL] [Abstract][Full Text] [Related]
6. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
7. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
8. Rutin-encapsulated chitosan nanoparticles targeted to the brain in the treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Naqvi AA; Alam MA; Ashafaq M; Samim M; Iqbal Z; Ahmad FJ
Int J Biol Macromol; 2016 Oct; 91():640-55. PubMed ID: 27264648
[TBL] [Abstract][Full Text] [Related]
9. Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives.
Hassan RH; Gad HA; El-Din SB; Shaker DS; Ishak RAH
Int J Pharm; 2022 Nov; 628():122278. PubMed ID: 36243325
[TBL] [Abstract][Full Text] [Related]
10. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
11. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
12. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting.
Pandey M; Choudhury H; Gunasegaran TAP; Nathan SS; Md S; Gorain B; Tripathy M; Hussain Z
Drug Deliv Transl Res; 2019 Apr; 9(2):520-533. PubMed ID: 29488170
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Bromocriptine-Mesylate-Loaded Polycaprolactone Nanoparticles Coated with Chitosan for Nose-to-Brain Delivery: In Vitro and In Vivo Studies.
Badran MM; Alanazi AE; Ibrahim MA; Alshora DH; Taha E; H Alomrani A
Polymers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835942
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
16. Development and optimization of in-situ gel containing chitosan nanoparticles for possible nose-to-brain delivery of vinpocetine.
Hard SAAA; Shivakumar HN; Redhwan MAM
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127217. PubMed ID: 37793522
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
18. A Novel Delivery Method of Cyclovirobuxine D for Brain-Targeting: Chitosan Coated Nanoparticles Loading Cyclovirobuxine D by Intranasal Administration.
Wei H; Lai S; Wei J; Yang L; Jiang N; Wang Q; Yu Y
J Nanosci Nanotechnol; 2018 Aug; 18(8):5274-5282. PubMed ID: 29458577
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer.
Ahmad N; Alam MA; Ahmad R; Naqvi AA; Ahmad FJ
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):432-446. PubMed ID: 28503995
[TBL] [Abstract][Full Text] [Related]
20. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
